Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03748186 · ClinicalTrials.gov registry record · Phase 1
Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers
A Phase 1 study, sponsored by Sutro Biopharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 136
- Enrollment target
NCT03748186: Completed Phase 1 study, sponsored by Sutro Biopharma.
NCT03748186 is a Phase 1 study that has completed, run by Sutro Biopharma. The registered enrollment target is 136 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (127% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03748186, a Phase 1 study, has completed, sponsored by Sutro Biopharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 136 participants
- Enrollment target
Study Summary
Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-002 given intravenously every 3 weeks.
Primary Outcome
Incidence of adverse events (AEs) observed across STRO-002 dose levels
Interventions
- DRUG STRO-002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2019-02-01 |
| Est. Completion | 2024-06-04 |
| Phase | Phase 1 |
What the finished NCT03748186 record still lists
NCT03748186 is an interventional study that assigns participants to a tested intervention. The registered 136 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (127% higher).
The record links to 0 conditions, and to 1 intervention - of which STRO-002 is the first listed.
NCT03748186 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03748186 about?
NCT03748186 is a clinical study titled "Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers". Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-002 given intravenously every 3 weeks.
What is the current status of trial NCT03748186?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 136 participants. The study started on 2019-02-01. Estimated completion is 2024-06-04.
What interventions are being tested in trial NCT03748186?
The interventions under investigation include: STRO-002 (DRUG).
Who is sponsoring clinical trial NCT03748186?
This trial is sponsored by Sutro Biopharma, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03748186's enrollment target sits among peer trials
136 422nd of 2000 higher than 1,576 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01555892 · 136 participants · Phase 1
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- NCT03216525 · 136 participants · Phase 3
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
- NCT04476901 · 136 participants · Phase 2
Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy
- NCT04603898 · 136 participants · NA
Oxalate Formation From Ascorbic Acid
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI